Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) and InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Insider and Institutional Ownership
63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Reviva Pharmaceuticals and InMed Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reviva Pharmaceuticals | N/A | N/A | -$19.86 million | ($4.06) | -0.10 |
| InMed Pharmaceuticals | $4.94 million | 1.00 | -$8.16 million | ($2.89) | -0.51 |
InMed Pharmaceuticals has higher revenue and earnings than Reviva Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Reviva Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Profitability
This table compares Reviva Pharmaceuticals and InMed Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reviva Pharmaceuticals | N/A | -391.58% | -119.08% |
| InMed Pharmaceuticals | -132.87% | -80.85% | -68.11% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Reviva Pharmaceuticals and InMed Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reviva Pharmaceuticals | 1 | 2 | 5 | 0 | 2.50 |
| InMed Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Reviva Pharmaceuticals currently has a consensus target price of $66.67, suggesting a potential upside of 16,160.16%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than InMed Pharmaceuticals.
Summary
Reviva Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
